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SHORT ABSTRACT:  
Nanoparticles are emerging as promising drug delivery systems for a broad range of indications. 
Here, we describe a simple yet powerful method to manufacture silk nanoparticles using reverse 
engineered Bombyx mori silk. These silk nanoparticles can be readily loaded with a therapeutic 
payload and subsequently explored for drug delivery applications.  
 
LONG ABSTRACT:  
Silk is a promising biopolymer for biomedical and pharmaceutical applications due to its 
outstanding mechanical properties, biocompatibility and biodegradability, as well its ability to 
protect and subsequently release its payload in response to a trigger. While silk can be 
formulated into various material formats, silk nanoparticles are emerging as promising drug 
delivery systems. Therefore, this article covers the procedures for reverse engineering silk 
cocoons to yield a regenerated silk solution that can be used to generate stable silk nanoparticles. 
These nanoparticles are subsequently characterized, drug loaded and explored as a potential 
anticancer drug delivery system. Briefly, silk cocoons are reverse engineered first by degumming 
the cocoons, followed by silk dissolution and clean up, to yield an aqueous silk solution. Next, 
the regenerated silk solution is subjected to nanoprecipitation to yield silk nanoparticles Ð a 
simple but powerful method that generates uniform nanoparticles. The silk nanoparticles are 
characterized according to their size, zeta potential, morphology and stability in aqueous media, 
as well as their ability to entrap a chemotherapeutic payload and kill human breast cancer cells. 
Overall, the described methodology yields uniform silk nanoparticles that can be readily 
explored for a myriad of applications, including their use as a potential nanomedicine.  
 
INTRODUCTION:  
Nano-sized drug delivery systems are often used to control drug release and to deliver a diverse 
set of therapeutic payloads Ð for example, proteins, peptides and small molecular weight drugs Ð 
to target cells and tissues. These therapeutic payloads are often incorporated into various 
macromolecular drug carriers, such as liposomes, water soluble polymers (including 
dendrimers), and micro- and nanoparticles
1
. Nanoparticles (typically in a size range of 1 nm to 
1,000 nm) are being widely explored as potential drug carriers, particularly for anticancer drug 
delivery
2
. The successful introduction of Abraxane (120 nm sized albumin-based nanoparticles 
loaded with paclitaxel) into routine clinical practice
3
 has catalyzed the field, so that many more 
nanoparticles for drug delivery are now entering clinical trials
4
. Solid tumors generally show 
poor lymphatic drainage and have leaky blood vessels which means that nanoparticles of up to 
200 nm will be passively targeted to these tumors following intravenous administration. This 
passive targeting phenomenon is called the enhanced permeability and retention (EPR) effect and 
was first reported in 1986
5
. The EPR effect can lead to a 50 to 100 fold increase in drug 
concentrations within the tumor microenvironment for a given drug dose when the drug payload 
is delivered using a macromolecular drug carrier approach rather than the free drug without the 
carrier. Drug-loaded nanoparticles designed for anticancer drug delivery have to reach the tumor 
microenvironment and often must enter a specific intracellular compartment, usually by 
endocytic uptake, for the drug to achieve its desired therapeutic effect
3
. Nanoparticles designed 
for intracellular drug delivery exploit endocytosis as a gateway into the cell as well as a route to 
overcome drug resistance mechanisms. Drug release from nanoparticles is often specifically 
designed to occur in lysosomes (i.e. lysosomotropic drug delivery)
6
 where the pH responsiveness 
of the nanoparticle carrier (lysosomal pH approximately 4.5) can serve as trigger for drug release 
or lysosomal enzymes that liberate the payload from the carrier
7
. 
 
Many different classes of materials can be used to generate nanoparticles (e.g. metals and many 
organic and inorganic materials). However, biopolymers are emerging as attractive materials 
because of their known biocompatibility, biodegradability and low toxicity
8
. Many biopolymers 
are being explored, including albumin, alginate, chitosan and silk. Of these, silk has emerged as a 
promising contender for development into drug delivery systems
9
. Silks of various types are 
produced by a number of arthropods, including spiders (e.g. Nephila clavipes) and silkworms 
(e.g. Bombyx mori). Silkworm silk is used far more extensively than spider silk because the 
silkworm is fully domesticated and its silk thus represents a reproducible starting material. 
Silkworm silk is a Food and Drug Administration (FDA) approved material for human use, 
particularly as a suture material; it has a robust safety record in humans and is known to degrade 
in vivo
10
. The degradation profile of silk can be fine-tuned to range from hours (low crystalline 
silk) to 12 months or more (high crystalline silk). Silk degradation products are non-toxic and are 
metabolized in the body
10
. The silk structure imparts the ability to bind small molecular weight 
compounds and macromolecular protein drugs
11
, making it a good material for controlled drug 
release. Protein drugs (e.g. antibodies) are susceptible to denaturation, aggregation, proteolytic 
cleavage and clearance by the immune system. However, silk stabilizes therapeutic proteins due 
to the buffering capacity of its nanocrystalline regions and its ability to tailor water content at the 
nanoscale
11
. These unique features provide physical protection and reduce payload mobility
11
 
and are typically not seen with other (bio)polymers. Many anticancer drug delivery systems, for 
example silk-based hydrogels
12
, films
13-15 
and nanoparticles
16,17
 , have now been developed to 
exploit these features (reviewed in 
18,19
 ) 
 
Here, silk nanoparticles were characterized by determining their size and charge over an 
extended time frame. Doxorubicin, a clinically relevant anticancer drug, was used as a model 
drug for drug loading and cytotoxicity studies in triple negative human breast cancer cells treated 
with drug-loaded silk nanoparticles.  
 
PROTOCOL:  
 
1. Preparation of a reverse-engineered silk solution from Bombyx mori cocoons 
 
Note: This methodology is based on protocols described elsewhere 
12,27
. 
 
1.1) Cut 5 g of dried cocoons with scissors into 5 mm ! 5 mm pieces. Remove any soiled 
layers.  
 
1.2) Weigh out 4.24 g of sodium carbonate and add this carefully to 2 L of boiling distilled 
water. 
 
Note: This yields a 0.02 M sodium carbonate solution. 
 
1.3) Add the cut cocoon pieces to the boiling sodium carbonate solution and boil for 60 
minutes to degum the silk fibers. Stir the silk occasionally to ensure homogenous sample 
processing. 
 
1.4) Remove the degummed silk and wash with 1 L of distilled water for 20 minutes; repeat 
the washing step at least 3 times. 
 
1.5) Remove the washed silk and squeeze it well to remove excess liquid and then untie/pull 
the silk by hand. Place the untied silk in a fume hood to air dry overnight. This typically yields 
3.6 g of degummed silk fibers. 
 
1.6) The next day, weigh out 5 g air-dried degummed silk fibers and pack the silk tightly into 
the bottom of a 50 mL beaker. 
 
1.7) Prepare a fresh 9.3 M LiBr solution. Dissolve the silk fibers in LiBr using a 1 g silk to 4 
mL LiBr ratio. Cover the silk LiBr sample with aluminum foil to prevent evaporation and allow 
the silk to dissolve completely at 60¡C. This step takes up to 4 hours and is aided by occasionally 
stirring.  
 
1.8) Wet a dialysis cassette (molecular weight cut-off of 3,500 Da) in water for 5 minutes. 
Inject 15 mL the silk LiBr solution into the 15 mL dialysis cassette and use a needle and syringe 
to remove any air bubbles. 
 
1.9) Dialyze against 1 L of distilled water and change the water at 1, 3 and 6 hours (i.e. 3 
changes on the first day) and again on the next morning and evening (i.e. 2 changes on the 
second day), and again on the following morning (i.e. 1 change on the third day). 
 
1.10) Collect the silk solution from the dialysis cassette and centrifuge the solution for 20 
minutes at 5 ¡C at 9500 x g. Recover the supernatant and repeat this centrifugation process twice 
more. 
 
1.11) Determine the weight of an empty weighing boat (W1) and add 1 mL of the silk solution. 
Record the weight again (W2) and then dry the sample by leaving the weighing boat at 60 ¼C 
overnight. Next, determine the total dry weight (W3) (dried silk and weighing boat). The 
concentration of the silk solution (w/v) is: % = (W3-W1/W2-W1) x 100. 
 
2. Preparation of silk nanoparticles from reverse-engineered silk solution 
 
2.1) Add a 5% (w/v) silk solution dropwise to acetone while maintaining a >75% (v/v) 
acetone solution. For example, add 9 mL of a 5% (w/v) silk solution dropwise (10 µl/drop at a 
rate of 50 drops/minute) to 34 mL acetone. 
 
2.2) Centrifuge the precipitate at 48,000 x g for 2 hours at 4 ¡C.  
 
2.3) Aspirate the supernatant and resuspend the pellet in distilled water by first dislodging the 
pellet with a spatula and then adding 20 mL distilled water. Use pipet tips to remove the pellet 
from the spatula. After vortexing for 20 seconds followed by two sonication cycles using an 
ultrasonic probe at 30% amplitude for 30 seconds, top up the centrifuge tube to capacity with 
distilled water.  
 
2.4) Repeat the centrifugation and resuspension step at least twice. 
 
2.5) Resuspend the pellet in 6 mL distilled water, as detailed in 2.3 and store at 4 ¡C until use. 
For cell culture studies, silk nanoparticle stocks can be gamma irradiated 
17
.  
 
3. Determination of silk nanoparticle concentration 
 
3.1) Centrifuge silk nanoparticles at 48,000 x g for 2 hours at 4 ¡C. 
 
3.2) Collect all nanoparticles in 3 mL of distilled water, followed by two sonication cycles at 
30% amplitude for 30 seconds.  
 
3.3) Divide the 3 mL stock of silk nanoparticles into 2 mL and 1 mL lots and transfer into pre-
weighed 2 mL tubes. Record the total weight of the 2 mL sample. Store the 1 mL lot at 4 ¡C until 
use; this 1 mL sample will be used to generate a calibration curve. 
 3.4) Snap freeze and then lyophilize the 2 mL silk nanoparticle lot in a freeze dryer overnight. 
After freeze-drying, reweigh the 2 mL tube and calculate the amount of silk nanoparticles (mg) 
that was originally present in the 2 mL sample. 
 
3.5) Dilute the 1 mL silk nanoparticle stock with distilled water to generate a 5-point 
calibration curve (0.04 Ð 7 mg/mL). Ensure that samples do not exceed the absorbance 
maximum.  
 
3.6) Determine the absorbance of each standard dilution at 600 nm. This is best done using a 
96-well plate setup. Plot absorbance versus concentration (mg/mL) for the standard curve. Then 
use this standard curve routinely to determine the concentration of silk nanoparticles in 
suspensions. 
 
4. Preparation of doxorubicin-loaded silk nanoparticles 
 
4.1) Preparation of the doxorubicin solution 
 
4.1.1) Dissolve 1.2 mg of doxorubicin HCl in 8 mL distilled water. 
 
4.1.2)  Make up to 10 mL with distilled water to yield a working stock of 116 µg/mL (0.2 
µmol/mL). 
 
4.2) Preparation of doxorubicin-loaded silk nanoparticles 
 
4.2.1) Mix 2 mL of 0.2 µmol/mL doxorubicin solution with 200 µL of 10, 30 or 50 mg/mL of 
silk nanoparticles in a 2 mL tube. 
 
4.2.2) Incubate the silk-doxorubicin suspension at room temperature (25 ¡C) overnight on a 
rotating mixer. 
 
4.2.3) Next, centrifuge the silk-doxorubicin suspension at 194,000 x g for 30 minutes. Wash the 
doxorubicin-loaded silk nanoparticles with distilled water and repeat this procedure twice more.  
 
4.2.4) Pool the supernatant and note the total volume (this sample is used to determine the 
encapsulation efficiency). 
 
4.2.5) Resuspend the doxorubicin-loaded silk nanoparticles in distilled water, protect from light 
and store at 4 ¼C until use. 
 
4.3) Determination of encapsulation efficiency and drug loading 
 
4.3.1)  Pipet 200 µL of the supernatant from step 4.2.4 into a black microtiter plate.  
 
4.3.2) Use a fluorescence microplate reader to measure doxorubicin-associated fluorescence at a 
fixed photomultiplier setting. 
 4.3.3) Set the excitation wavelength to 485 nm and emission wavelength to 590 nm and record 
the fluorescence values. 
 
4.3.4) Generate a doxorubicin calibration curve. Ensure measurements are acquired with 
identical instrument settings (i.e. with a fixed photomultiplier setting). Using the calibration 
curve, calculate the doxorubicin concentration in the combined supernatant. Repeat this 
measurement in three independent experiments. 
 
4.3.5) Use equation (1) to determine encapsulation efficiency: 
 
(1)  Encapsulation efficiency (%) =  amount of model drug in nanoparticles x 100 
                                          model drug initially added 
 
5. Characterization of silk nanoparticles  
 
5.1) Assessment of the size and zeta potential of freshly prepared and stored silk 
nanoparticles. 
 
5.1.1) Store silk nanoparticles in distilled water at 4 ¡C and 25 ¡C. 
 
5.1.2) Measure the size and zeta potential of the silk nanoparticles on days 0, 14 and 28 using 
dynamic light scattering (DLS). Set refractive indices to 1.33 for distilled water and 1.60 for 
protein 
17
. Calculate particle sizes with the user interface software. 
 
5.2) Morphological assessment of silk nanoparticles by scanning electron microscopy (SEM). 
 
5.2.1) Place a carbon adhesive disc onto an SEM stub and subsequently attach a silicon wafer.  
 
5.2.2) Dilute silk nanoparticles to a concentration of 1 mg/mL. Pipette 10 µL of the sample onto 
a silicon wafer, freeze the sample at -80¡C and lyophilize overnight using a freeze drying system 
as per manufacturerÕs instructions. 
 
5.2.3) Coat the sample with a gold layer up to 20 nm thick using a low vacuum sputter coater. 
 
Note: Instrument settings vary between models. The model used here is fully automated and 
operates by thickness only. 
 
5.2.4) Image samples with a scanning electron microscope at 5 kV and a 40,000-fold 
magnification. 
 
6. In vitro cytotoxicity of control and doxorubicin-loaded silk nanoparticles  
 
6.1) Cell viability following exposure to silk nanoparticles. 
 
6.1.1) Culture MDA-MB-231 cells in RPMI 1640 with 10%v/v FBS. Plate cells on tissue 
culture treated polystyrene and incubate in a humidified 5% CO2 atmosphere at 37 ¡C. Routinely 
subculture at 80% confluence every 2−3 days. 
 
6.1.2) Plate MDA-MB-231 cells at a density of 2 x 10
4
 cells/cm
2
 in 96-well plates. Allow the 
cells to recover overnight. 
 
6.1.3) Add (i) 0.001-1 µg freely diffusible doxorubicin, (ii) 0.001-0.5 mg silk nanoparticles and 
0.1 mg silk nanoparticles loaded with 0.001-1 µg doxorubicin into 96-well plates (final volume 
100 µL per well). 
 
6.1.4) Determine cell viability and the half maximal inhibitory concentration (IC50) by adding (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT 5 mg/mL in PBS) at 72 hours. 
Incubate for 5 hours, carefully drain the wells with a pipette and dissolve the formazan with 100 
µL of dimethylsulfoxide. Measure the absorbance at 560 nm. Repeat this measurement in three 
independent experiments. 
 
Note: The absorbance values of untreated controls serve as a reference value for 100% cell 
viability.  
 
6.2) SEM of cells exposed to silk nanoparticles.  
 
6.2.1) Seed MDA-MB-231 cells on sterile glass coverslips at a density of 2 x 10
4
 cells/cm
2
. 
Allow the cells to recover overnight. Expose the cells to the desired treatment conditions for 72 
hours.  
 
6.2.2) Fix the cells with 2% v/v glutaraldehyde in PBS for 30 minutes, wash with distilled water 
twice, dehydrate with an ethanol series, and critical point dry the samples, as detailed 
elsewhere
28
. 
 
6.2.3) Sputter coat the samples with a gold layer up to 20 nm thick using a low vacuum sputter 
coater. 
 
Note: Instrument settings vary between models. The model used here is fully automated and 
operates by thickness only. 
 
6.2.4) Image the samples by SEM using an electron acceleration of 5 kV and 700-fold 
magnification. 
 
REPRESENTATIVE RESULTS:  
Data were statistically analyzed as detailed previously
17
. The StudentÕs t-test was used for 
sample pairs and one-way analysis of variance (ANOVA) followed by BonferroniÕs multiple 
comparison post hoc test for multiple samples. An asterisk denotes statistical significance as 
follows: *P < 0.05 and **P < 0.001. All data are presented as mean values ± standard deviation 
(SD) and the numbers in brackets indicate the number of independent experiments. 
 
Regenerated silk solution was prepared and subsequently added dropwise to acetone to generate 
silk nanoparticles via nanoprecipitation (Figure 1). This method yielded uniform (polydispersity 
index: 0.1), spherical, silk nanoparticles (106.5 nm ± 1.1) with a negative surface charge (-49.57 
mV ± 0.6) (Figure 2 and 3). Silk nanoparticle stability in water was assessed for up to 28 days by 
monitoring particles size, zeta potential and morphology (Figures 2 and 3). Over the 28 day 
storage period, at either 4 ¡C or 25 ¡C, no significant change in particle size, charge (Figure 2) or 
morphology was observed (Figure 3).  
 
Doxorubicin was used as a clinically relevant chemotherapeutic model drug for drug loading and 
in vitro cytotoxicity studies. Three different silk nanoparticle concentrations (10, 30 and 50 
mg/mL) were used to assess the drug loading capacity of the silk nanoparticles. The doxorubicin 
encapsulation efficiency for 10, 30 and 50 mg/mL silk nanoparticles (i.e. 2, 6 or 10 mg of silk 
and 232 µg of doxorubicin) was 73±2.2, 87±1.8 and 97±0.2%, respectively (Figure 4A). The 
particle size and zeta potential of doxorubicin-loaded silk nanoparticles (10 mg) were measured 
and compared to 10 mg silk nanoparticle controls. The particle size did not change after drug 
loading (Figure 4B), while the zeta potential of doxorubicin-loaded silk nanoparticles was 
significantly reduced from -49.57±0.6 mV to -43.52±0.37 mV (Figure 4C).  
 
The ability of drug-loaded silk nanoparticles to deliver doxorubicin and subsequently kill cancer 
cells was assessed in vitro. Human breast cancer MDA-MB-231 cells were exposed to silk 
nanoparticles, freely diffusible doxorubicin or doxorubicin-loaded silk nanoparticles. Cell 
viability was assessed after a 72 hours exposure period. The IC50 values of freely diffusible 
doxorubicin and doxorubicin-loaded silk nanoparticles were 0.48 µg/mL and 0.24 µg/mL, 
respectively while the silk nanoparticles had an IC50 > 5 mg/mL (Figure 5A). At equivalent drug 
doses of 0.1 µg, freely diffusible doxorubicin and doxorubicin-loaded silk nanoparticles caused 
significant decreases in cell viability of 83±11 and 65±11%, respectively (Figure 5B). However, 
freely diffusible doxorubicin showed a substantial greater cytotoxicity than doxorubicin-loaded 
silk nanoparticles. These quantitative measurements were corroborated by qualitative SEM 
imaging (Figure 5c). Here, control cultures showed high cellular density and a predominating 
mesenchymal MDA-MB-231 phenotype; similar observations were made for cultures exposed to 
silk nanoparticles. However, cultures exposed to doxorubicin showed a markedly different cell 
phenotype. At the equivalent doxorubicin dose, MDA-MB-231 cells treated with freely 
diffusible doxorubicin and doxorubicin-loaded silk nanoparticles showed a substantial reduction 
in cell numbers. Furthermore, many cells had a very broad and spread out morphology. Cultures 
exposed to doxorubicin-loaded silk nanoparticles showed evidence of nanoparticles (and their 
aggregates) associated with the plasma membrane (Figure 5C).  
 
Figure 1: The key steps to generate a reverse engineered silk solution and silk 
nanoparticles. First, silk cocoons are reverse engineered by cutting and then degumming them 
for 60 minutes (i.e. boiling) to yield degummed silk fibers. The fibers are dissolved in 9.3 M 
LiBr and then dialyzed against water for 72 hours. An aqueous 5%w/v silk solution is used to 
generate silk nanoparticles. The dropwise addition of silk into acetone leads to silk 
nanoprecipitation. Silk nanoparticles are washed and collect for subsequent use.  
 
Figure 2: Size and charge characterization of silk nanoparticles. Particle size and zeta 
potential of silk nanoparticles at 4 ¡C and 25 ¡C over 28 days. ±SD; error bars are hidden within 
the plot symbol when not visible, n = 3. 
 
Figure 3: Quality assessment of silk nanoparticles stored at 4 ¡C and 25 ¡C over 28 days. 
Silk nanoparticles were imaged using scanning electron microscopy (scale bar = 1 µm). 
 
Figure 4: Characterization of doxorubicin-loaded silk nanoparticles (Dox-SNPs). (A) 
Encapsulation efficiency of 232 µg doxorubicin in response to different amounts of silk 
nanoparticles (SNPs); 2, 6 and 10 mg of silk nanoparticles. The encapsulation efficiency for 10 
mg and 5 mg silk nanoparticles significantly increased when compared to 2 mg silk 
nanoparticles. (B) Particle size and (C) zeta potential of doxorubicin-loaded silk nanoparticles 
compared to control silk nanoparticles (10 mg of silk nanoparticles). Statistically significant 
differences for sample pairs were determined with StudentÕs t-test. Multiple samples were 
assessed by one-way ANOVA, followed by BonferroniÕs multiple comparison post hoc test; *P 
< 0.05, **P < 0.001, ±SD; error bars are hidden within the plot-symbol when not visible, n = 3. 
 
Figure 5: In vitro cytotoxicity of silk nanoparticles and doxorubicin-loaded silk 
nanoparticles in human breast cancer cells. (A) Cell viability of MDA-MB-231 cells after a 
72 hours treatment cycle with silk nanoparticles (SNPs) (0.01-5 mg/mL); volumes per well were 
100 µl. (B) Cell viability of MDA-MB-231 cells after a 72 hours treatment cycle with 0.1 mg 
silk nanoparticles, 0.1 µg of freely diffusible doxorubicin (Dox) or 0.1 mg of silk nanoparticles 
loaded with 0.1 µg of doxorubicin (Dox-SNPs). Cell viability was statistically decreased 
following the exposure to 0.1 µg of freely diffusible doxorubicin and 0.1 mg of silk nanoparticles 
loaded with 0.1 µg of doxorubicin when compared to the control. (C) SEM images of MDA-MB-
231 cells exposed to (i) medium (control), (ii) 0.1 mg silk nanoparticles, (iii) 0.1 µg of freely 
diffusible doxorubicin, and (iv) doxorubicin-loaded silk nanoparticles at equivalent doses (scale 
bar = 50 µm). Statistical analysis was performed by one-way ANOVA followed by BonferroniÕs 
multiple comparison post hoc test, ns = not significant, *P < 0.05, **P < 0.001, ±SD; error bars 
are hidden within the plot-symbol when not visible, n = 3. 
 
DISCUSSION:  
Various methods are available to produce silk nanoparticles, including polyvinyl alcohol 
blending
20
, spray drying
21
, salting out
22
, capillary microdot printing
23
, supercritical CO2 
precipitation
24
 and nanoprecipitation
16,25
 (reviewed in 
26
) However, nanoprecipitation, due to its 
overall simplicity, is the most popular technique for generating silk nanoparticles. Therefore, the 
purpose of this study was to apply nanoprecipitation to reverse-engineered silk to manufacture 
silk-based nanoparticles that can be used for a range of applications, including lysosomotropic 
anticancer drug delivery.  
 
Over the past decade, nanoprecipitation has become one of the most common procedures for the 
manufacture of protein-based nanoparticles
29
. Our research group
16,17
 and others
25,26,30,31
 have 
successfully applied this technology to silk; here, we present a simple but robust stepwise 
protocol for the generation of silk nanoparticles. Acetone nanoprecipitation yields spherical silk 
particles that are homogeneous in size and fall typically in the nanometer size range. Acetone has 
emerged as the preferred continuous phase over solvents such as methanol, ethanol, isopropanol 
and butanol
16,25
. Acetone yields nanoparticles that have a reduced level of hydration when 
compared to the metastable 100Ð200 nm sized spherical micellar structures present in native and 
regenerated silk solutions
32
. However, there is scope to explore solvent mixtures and variations 
in degumming time in order to generate silk (nano)particles with potentially different properties 
to those described here. The protocol described here utilizes acetone as the continuous phase, 
which permits the manufacture of uniform spherical nano-sized silk particles (106.5±1.1 nm) that 
carry a negative surface charge (-49.57±0.6 mV) and that have a tight packing of the 
hydrophobic, crystalline silk chains
16,17
. Overall, the described procedure requires little hands-on 
time and yields silk nanoparticles from a reverse-engineered aqueous silk solution (Figure 1). 
Some of the key features of this procedure include the use of 60 minutes degummed silk, the 
appropriate drop size (approximately 10 µl/drop) and a maximum dropping rate of 50 
drops/minute. Adherence to these key features results in a typical yield of 14%. These 
nanoparticles are robust and we provide evidence that they are stable and do not change their 
physical characteristics over a 28-day storage period. However, a potential caveat of the 
described method is the absence to generate particles over a broad size range (i.e. generating 
particles from the nanometer to micrometer scale while maintaining a narrow polydispersity 
index). 
 
Controlling particle size, charge and shape is important for drug delivery, particularly when 
targeting solid tumors
33
. Particles in the 100 nm size range are emerging as ideal candidates for 
tumor targeting. Therefore, 100 nm sized silk nanoparticles are potential contenders as anticancer 
drug delivery systems for solid tumor treatments. Silk nanoparticles have a negative surface 
charge, which renders them easily loaded with positively charged drugs through exploitation of 
the electrostatic interaction
16
. However, besides charge, additional drug characteristics (e.g. 
logD) are also known to affect drug loading and release
34
. In the present study, doxorubicin, a 
weakly basic anticancer drug, was selected as a model drug candidate. The drug loading study 
(Figure 4) showed that increasing the silk nanoparticle concentration led to increased 
doxorubicin encapsulation efficiency; 10 mg of silk nanoparticles can encapsulate 232 µg of 
doxorubicin. Drug loading of the silk nanoparticles, in turn, resulted in silk nanoparticles with a 
significantly reduced surface charge, which was direct experimental evidence confirming that the 
doxorubicin-silk charge interaction is important for this particular drug carrier combination. 
 
We have previously provided evidence that silk nanoparticles can serve as a lysosomotropic drug 
delivery system
16,17
. Here, we show a test using doxorubicin-loaded silk nanoparticles to treat the 
human breast cancer MDA-MB-231 cell line. These cells are derived from a highly invasive 
triple negative breast cancer (ER
-
/PR
-
/HER2
-
) that is difficult to treat in the clinic
35
. Therefore, 
designing a drug delivery system tailored to this patient population is expected to yield 
tremendous benefits. In the absence of drug loading, silk nanoparticles did not affect cell 
viability (IC50 values > 5 mg/mL) (Figure 5a, c). However, at equivalent doses, significantly 
greater cytotoxicity was observed with freely diffusible doxorubicin than with doxorubicin-
loaded silk nanoparticles (Figure 5b). The differences between the in vitro cellular 
pharmacokinetics of freely diffusible and particle bound drug explain this observation. The 
freely diffusible drug can rapidly cross the plasma membrane via diffusion, whereas uptake of 
the drug-loaded nanoparticles relies on endocytosis. Nonetheless, endocytic uptake of 
nanoparticles can enhance drug retention and overcome drug resistance mechanisms
3
. However, 
the true benefit of nanoparticle-mediated anticancer drug delivery is that it exploits the EPR 
effect to facilitate passive tumor targeting and to improve pharmacokinetics. Therefore, the use 
of a nanoparticle-based drug delivery approach can only be fully assessed in vivo. In vitro studies 
have limitations (i.e. the absence of the EPR effect) that preclude the full characterization of 
these types of drug delivery systems
7
.  
 
In summary, the described methodology allows the easy manufacture of spherical silk 
nanoparticles of consistent size and surface charge. These silk nanoparticles can be used for a 
broad range of applications (e.g., cosmetics, templates for nano patterning, theranostics, 
lubricants, control particles for nanotoxicity studies), including their use as anticancer drug 
delivery platforms.  
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